Clinical Trial Detail

NCT ID NCT03311555
Title A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Recruitment Active, not recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Tian Zhang, MD
Indications

prostate cancer

Therapies

Apalutamide + Docetaxel

Age Groups: adult senior

No variant requirements are available.